Mechanism of Action of 2-Aminobenzamide HDAC Inhibitors in Reversing Gene Silencing in Friedreich’s Ataxia

por Soragni, Elisabetta, Chou, C. James, Rusche, James R., Gottesfeld, Joel M.
Publicado 2015

Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich's Ataxia: A New Synthetic Route

por Xu, Chunping, Soragni, Elisabetta, Jacques, Vincent, Rusche, James R., Gottesfeld, Joel M.
Publicado 2011

Development of Frataxin Gene Expression Measures for the Evaluation of Experimental Treatments in Friedreich’s Ataxia

por Plasterer, Heather L., Deutsch, Eric C., Belmonte, Matthew, Egan, Elizabeth, Lynch, David R., Rusche, James R.
Publicado 2013

Histone deacetylases 1 and 2 maintain S-phase chromatin and DNA replication fork progression

por Bhaskara, Srividya, Jacques, Vincent, Rusche, James R, Olson, Eric N, Cairns, Bradley R, Chandrasekharan, Mahesh B
Publicado 2013

The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington’s Disease Mice

por Jia, Haiqun, Wang, Ying, Morris, Charles D., Jacques, Vincent, Gottesfeld, Joel M., Rusche, James R., Thomas, Elizabeth A.
Publicado 2016

Two New Pimelic Diphenylamide HDAC Inhibitors Induce Sustained Frataxin Upregulation in Cells from Friedreich's Ataxia Patients and in a Mouse Model

por Rai, Myriam, Soragni, Elisabetta, Chou, C. James, Barnes, Glenn, Jones, Steve, Rusche, James R., Gottesfeld, Joel M., Pandolfo, Massimo
Publicado 2010

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model

por Sandi, Chiranjeevi, Pinto, Ricardo Mouro, Al-Mahdawi, Sahar, Ezzatizadeh, Vahid, Barnes, Glenn, Jones, Steve, Rusche, James R., Gottesfeld, Joel M., Pook, Mark A.
Publicado 2011